Novel method uses cell-secreted microvesicles to regenerate heart muscle | Phase I study for HIV vaccine begins | Magellan Rx reports on hemophilia management program
April 24, 2018
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Novel method uses cell-secreted microvesicles to regenerate heart muscle
Columbia University researchers have developed a novel technique to regenerate damaged heart tissue using extracellular vesicles secreted by cardiomyocytes. The findings, reported in the journal Nature Biomedical Engineering, could help scientists develop new treatments for cardiac medical conditions.
United Press International (4/23) 
LinkedIn Twitter Facebook Google+ Email
$256,206 in average annual savings
The Verax Platelet PGD test improves platelet safety, extends shelf life, and protects your bottom line. PGD users who extend platelet dating to seven days save an average of more than $250,000 a year. Maybe it's time for you to join them. Learn more.
Science & Health
Phase I study for HIV vaccine begins
An early-stage study was launched by researchers at the University of Massachusetts to assess the safety of a potential vaccine for HIV. The clinical trial, which will take place at four sites, will include one group of patients that will receive the priming-booster regimen and another group that will get the DNA vaccine and the protein vaccine simultaneously.
MD Magazine online (4/23) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
Magellan Rx reports on hemophilia management program
Magellan Health's pharmacy benefit management division Magellan Rx reported that its hemophilia management program has resulted in reduced potential waste, with no reports of breakthrough bleeding among patients who had dose reductions.
Hemophilia News Today (4/23) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Autolus acquires UCL's CAR-T cell therapy for B-cell malignancies
Autolus acquired worldwide rights to develop and commercialize UCL Business' AUTO1, a CD19 chimeric antigen receptor T-cell therapy to treat B-cell malignancies. The drug candidate is being evaluated in early-stage studies for acute lymphoblastic leukemia in children and adults.
BioCentury (4/23) 
LinkedIn Twitter Facebook Google+ Email
Israeli immunotherapy firm to raise $10M to support GVHD research
Enlivex Therapeutics, which is working on a treatment for graft-versus-host disease, signed a nonbinding memorandum of understanding with Korea Investment Partners for a $2 million investment. Enlivex shareholder Hadasit Bio-Holdings will also invest $1.2 million as part of the agreement, and both parties will recruit other investors to complete a funding round of $6 million to $10 million.
Globes (Israel) (4/23),  Haaretz (Tel Aviv, Israel)/TheMarker (Tel Aviv, Israel) (4/24) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
Astellas seeks FDA nod for certain AML population
A new-drug application was submitted to the FDA by Astellas Pharma for its Gilteritinib, which is being developed as a treatment for patients with FLT3MUT+ relapsed or refractory acute myeloid leukemia.
Reuters (4/23) 
LinkedIn Twitter Facebook Google+ Email
EU approves Pfizer's Mylotarg for certain type of AML
Pfizer's Mylotarg, or gemtuzumab ozogamicin, was approved in combination with chemotherapy agents daunorubicin and cytarabine by the European Commission as a treatment for patients at least 15 years old who have previously untreated de novo CD33-positive acute myeloid leukemia.
Seeking Alpha (free registration) (4/23) 
LinkedIn Twitter Facebook Google+ Email
Association News
AABB to host eCast on cellular products for regeneration and immunotherapy
AABB will host an eCast, "HOT TOPIC: Harnessing the Power of Cellular Products for Regeneration and Immunotherapy," tomorrow, April 25, at 2 p.m. Eastern time. This program will focus on novel approaches for cell therapy using blood and bone marrow cell components for treatment. In addition, it will describe quality control methods for generation of cell therapy products and explore case studies from clinical trials.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Lead Laboratory Technologist
Simplicity is the shortest path to a solution.
Ward Cunningham,
computer programmer
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information